Investigational drug · Phase 2
RO7446603
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diabetic Macular Edema.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "RO7446603"
First trial start
2022
Jun 22, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RO7446603", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Macular Edema
Approved drugs for the same conditions: Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "RO7446603" as an intervention, largest first.
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular EdemaPivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT06850922 · 388 participants · Start Jun 22, 2022 · Primary completion May 19, 2026
Drug: RO7446603; Aflibercept and 1 more · For: Diabetic Macular Edema
Sites: Phoenix, Arizona; Springdale, Arkansas; Campbell, California · 77 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Diabetic Macular Edema
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- EYP-1901Phase 34 trials
EyePoint Pharmaceuticals, Inc. · Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- OCS-01Phase 32 trials
Oculis · Diabetic Macular Edema
- AVT29proposed aflibercept HD biosimilarPhase 31 trial
Alvotech Swiss AG · Diabetic Macular Edema
- Intravitreal RanibizumabPhase 31 trial
Roche (Genentech) · Diabetic Macular Edema
- BI 3812465Phase 21 trial
Boehringer Ingelheim · Diabetic Macular Edema
- CU06-1004Phase 21 trial
Curacle Co., Ltd. · DME, Diabetic Macular Edema, Diabetic Macular Edema (DME)
- OXU-001DEXAspheresPhase 21 trial
Oxular Limited · Diabetic Macular Edema
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.